BRAF抑制剂的悖论性活性:在伤口愈合中的潜在用途
Sonali Karhana1, Mohd Samim2, Nidhi1
1Department of Translational & Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.
Archives of dermatological research
|January 28, 2025
概括
用于癌症的BRAF抑制剂可以通过利用它们悖论性的活性来加速伤口愈合. 本综述探讨了它们在老龄化人口中治疗慢性伤口的潜力.
科学领域:
- 伤口愈合研究研究研究
- 瘤学药物重新使用
背景情况:
- 慢性伤口是一个重大挑战,特别是在老年人群中,患有糖尿病等并发症.
- 目前的伤口护理策略往往不足,需要创新方法来加速愈合.
研究的目的:
- 审查V-RAF鼠肉瘤病毒瘤同源B1 (BRAF) 抑制剂在加速伤口愈合方面的潜力.
- 探索BRAF抑制剂矛盾活性背后的机制及其在伤口修复中的应用.
主要方法:
- 在PubMed,Scopus,谷歌学者和科学网络的系统文献搜索.
- 对文章的选与BRAF抑制剂悖论性活性,机制和伤口愈合应用的相关性.
- 评估来自体外,体内和临床研究的证据.
主要成果:
- BRAF抑制剂表现出矛盾的活性,导致基激活蛋白激酶 (MAPK) 路径激活和皮肤过度增殖.
- 有证据表明,BRAF抑制剂可以增强上皮质化和血管生成,这对于伤口修复至关重要.
- 研究表明,在急性和慢性伤口治疗中,BRAF抑制剂可能会被重新使用.
结论:
- BRAF 抑制剂显示为促进伤口愈合的新型治疗策略.
- 对BRAF抑制剂在伤口护理中的机制和临床应用的进一步研究是有必要的.
- 重用抗癌药物,如BRAF抑制剂,为管理具有挑战性的伤口提供了新的途径.
相关概念视频
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K


